Comparative efficacy of five Chinese medicine injections for treating dilated cardiomyopathy with heart failure: A Bayesian network meta-analysis

• Published in: Journal of ethnopharmacology 2022-01, Vol.282, p.114604-114604, Article 114604
• Main Authors: Cao, Xinfu, Liu, Hongxu, Zhou, Mingxue, Chen, Xiufen, Long, Dehuai
• Format: Article
• Language: English
• Subjects: Astragalus propinquus; Bayes Theorem; Cardiomyopathy, Dilated - complications; Cardiomyopathy, Dilated - diagnostic imaging; Cardiovascular Agents - pharmacology; Chinese medicine injections; Dilated cardiomyopathy; Drug Combinations; Drug Therapy, Combination - methods; Drugs, Chinese Herbal - pharmacology; Heart failure; Heart Failure - diagnosis; Heart Failure - drug therapy; Heart Failure - etiology; Humans; Injections; Network meta-analysis; Traditional Chinese medicine
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2021.114604

Chinese medicine injections (CMIs) are widely used by clinicians in China as an adjuvant treatment in dilated cardiomyopathy with heart failure (DCM-HF). However, comprehensive and systematic evidence supporting the beneficial effects of CMIs combined with Western medicine (WM) against DCM-HF was lacking. This network meta-analysis aimed to assess the effectiveness of five different CMIs in the treatment of DCM-HF. The Cochrane Library, Embase, PubMed, China National Knowledge Infrastructure (CNKI), Allied and Alternative Medieine Database (AMED), Chinese Biological Medicine Database (CBM), Wanfang Database, and Chinese Scientific Journal Database (VIP) were comprehensively searched from their inception to March 10, 2020, for randomized controlled trials (RCTs) focusing on the use of CMIs combined with WM to treat DCM-HF. The quality of the included RCTs was assessed using the Cochrane Handbook 5.1.0. Bayesian network meta-analysis were designed to access the effectiveness of different CMIs. A total of 38 eligible RCTs involving 3247 patients were enrolled. The study showed that Huangqi injection, Shengmai injection, Shenfu injection, Shenmai injection, and Xinmailong injection combined with WM significantly improved performance compared with WM alone in treating DCM-HF. Xinmailong injection + WM had the highest likelihood of being the best treatment in terms of the improvement in the clinical effectiveness rate, left ventricular end-diastolic dimension, and 6-min walking distance. Huangqi injection + WM had the highest probability of being the best treatment on account of the enhancement of left ventricular ejection fraction. Shenmai injection + WM had the highest likelihood of being the best treatment considering the improvement in cardiac output and the reduction in brain natriuretic peptide. The combination between CMIs and WM exerted a more positive effect in DCM-HF treatment. Xinmailong injection + WM had the best performance in treating DCM-HF, followed by Shenmai injection and Huangqi injection. However, due to the low qualities of the original studies, more high-quality studies are needed to support the findings. [Display omitted]